Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.33 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.33 |
| ▸ | PTGFR | P43088 | 1/20 | 0.33 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.33 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.33 |
| ▸ | CETP | P11597 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1151009 | 0.99 | ALDH1A1 (0.38) | L3MBTL1ALDH1A1CYP4F2CYP4A11TRPA1 | |
| SCHEMBL1106794 | 0.93 | L3MBTL1 (0.34) | L3MBTL1ALDH1A1CYP4F2CYP4A11TRPA1 | |
| SCHEMBL1106731 | 0.92 | L3MBTL1 (0.38) | L3MBTL1ALDH1A1CYP4F2CYP4A11POLB | |
| SCHEMBL5903202 | 0.81 | ALDH1A1 (0.46) | L3MBTL1ALDH1A1TRPA1POLBTRPV1 | |
| SCHEMBL5902320 | 0.80 | ALDH1A1 (0.47) | L3MBTL1ALDH1A1POLBMAPK1PKM | |
| SCHEMBL12138689 | 0.76 | ALDH1A1 (0.44) | L3MBTL1ALDH1A1POLBPKMLMNA | |
| SCHEMBL1106734 | 0.75 | ALDH1A1 (0.41) | L3MBTL1ALDH1A1TRPA1POLBPKM | |
| SCHEMBL14106381 | 0.75 | ALDH1A1 (0.40) | L3MBTL1ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL28232684 | 0.75 | CETP (0.52) | CYP4F2CYP4A11POLBCETPPKM | |
| SCHEMBL12138665 | 0.75 | ALDH1A1 (0.45) | L3MBTL1ALDH1A1POLBPKMLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2402300-B1 | Hydroxyl compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS INC (US) | 2016-05-25 | — | — | EP | claimed |
| US-20200189999-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS INC (US) | 2020-06-18 | — | — | US | disclosed |
| US-20190084908-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS INC (US) | 2019-03-21 | — | — | US | disclosed |
| US-20170073286-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. | 2017-03-16 | — | — | US | disclosed |
| US-20170073286-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. | 2017-03-16 | — | — | US | disclosed |
| US-9452964-B2 | Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-20150344389-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. | 2015-12-03 | — | — | US | disclosed |
| US-9006290-B2 | Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-9006290-B2 | Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-20140235723-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-20120035141-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT | ESPERION THERAPEUTICS, INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-20120035141-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT | ESPERION THERAPEUTICS, INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-8067466-B2 | Cycloalkyl-hydroxyl compounds and compositions for cholesterol management | ESPERION THERAPEUTICS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067466-B2 | Cycloalkyl-hydroxyl compounds and compositions for cholesterol management | ESPERION THERAPEUTICS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20080249166-A1 | Inhibiting hepatic fatty acid and sterol synthesis; use with statins; compounds such as cyclopropyl or cyclobutyl-functional hydroxy-functional alpha,gamma-alkanediacids | ESPERION THERAPEUTICS, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080249166-A1 | Inhibiting hepatic fatty acid and sterol synthesis; use with statins; compounds such as cyclopropyl or cyclobutyl-functional hydroxy-functional alpha,gamma-alkanediacids | ESPERION THERAPEUTICS, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| US-7405226-B2 | e.g. ethyl 11-[1-(t-butoxycarbonyl)cyclopropyl]-2,2-dimethyl-7-oxoundecanoate; peroxisome proliferator activated receptor antagonist; cholesterol reducing, anticarcinogenic, antiinflammatory agent; aging, Alzheimer's Disease, cardiovascular disease, diabetic retinopathy, dyslipidemia, insulin resistance | PFIZER INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-7119221-B2 | treating and preventing a variety of diseases and conditions such as aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic retinopathy, dyslipidemia, dyslipoproteinemia, hypertension, impotence, insulin resistance, peroxisome proliferator activated receptor associated disorders | ESPERION THERAPEUTICS, INC. (US) | 2006-10-10 | — | — | US | disclosed |
| EP-1597223-A2 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | Esperion Therapeutics Inc. (US) | 2005-11-23 | — | — | EP | disclosed |
| WO-2004067489-A2 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035141-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT | PNLIP, NR1H3, NR1H2 | L3MBTL1 3579/4885ALDH1A1 1851/4885CYP4F2 1915/4885 |
| US-20140235723-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | PNLIP, NR1H3, NR1H2 | L3MBTL1 3518/4885ALDH1A1 2139/4885CYP4F2 2014/4885 |
| US-20150344389-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | PNLIP, NR1H3, NR1H2 | L3MBTL1 3518/4885ALDH1A1 2139/4885CYP4F2 2014/4885 |
| US-20190084908-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | PNLIP, NR1H3, NR1H2 | L3MBTL1 3518/4885ALDH1A1 2139/4885CYP4F2 2014/4885 |
| US-20200189999-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | PNLIP, NR1H3, NR1H2 | L3MBTL1 3518/4885ALDH1A1 2139/4885CYP4F2 2014/4885 |
| US-20080249166-A1 | Inhibiting hepatic fatty acid and sterol synthesis; use with statins; compounds such as cyclopropyl or cyclobutyl-functional hydroxy-functional alpha,gamma-alkanediacids | PNLIP, NR1H3, NR1H2 | L3MBTL1 3202/4885ALDH1A1 914/4885CYP4F2 713/4885 |
| US-20170073286-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | PNLIP, NR1H3, NR1H2 | L3MBTL1 3518/4885ALDH1A1 2139/4885CYP4F2 2014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.